Merck’s Gerberding advocates for a head start on the next pandemic, beginning now: a BioCentury audio interview 

First and foremost, the biopharma industry’s lesson from COVID-19 must be to advocate for the kinds of government engagement and investment that can provide a robust platform of countermeasures standing by for the next time they’re needed, according to Merck’s Julie Gerberding, a former CDC chief.

Gerberding, who is EVP and chief patient officer at Merck & Co. Inc. (NYSE:MRK), spoke to BioCentury on an audio interview as part of a series of one-on-one conversations with industry leaders for BioCentury’s 2020 Back to School package (see Cover Story:  “The Imperative of COVID-19”)...